Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000245532 | SCV000320438 | uncertain significance | Cardiovascular phenotype | 2021-02-23 | criteria provided, single submitter | clinical testing | The p.A36V variant (also known as c.107C>T), located in coding exon 2 of the CACNA1C gene, results from a C to T substitution at nucleotide position 107. The alanine at codon 36 is replaced by valine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species, and valine is the reference amino acid in in other vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Labcorp Genetics |
RCV001063656 | SCV001228513 | benign | Long QT syndrome | 2023-11-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002461052 | SCV002757270 | uncertain significance | not provided | 2022-11-17 | criteria provided, single submitter | clinical testing | Identified as de novo in one individual with schizophrenia in a large scale whole exome sequencing study (Wang et al., 2022); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 35220405) |